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Compassionate use of medicinal products: a multicenter study 
Compassionate Use (CU) is a way of making available to patients with an unmet 
medical need a promising medicine wich has not been authorised for their 
condition. The main objective of this study was to describe the magnitude and 
profile of the CU in a sample of Andalusian public hospitals. As a secondary 
objective we wanted to analyze the evolution of these new treatment options 
under development. 
Methods: A cross-sectional study including all applications of CU in 2010. Setting: 7 
hospitals, 6 different provinces. Variables: center, clinical area, medicinal product, 
ATC classification, therapeutic indications, and approval by the EMA or AEMPS 
during the four following years.       
Results: A total of 194 applications regarding CU of drugs were submitted to the 
respective Pharmacy Committees. Among them we identified 27 different types of 
CU. Reina Sofía Hospital (Córdoba) was the most active center, both in number of 
applications (24%) and variety of them (15 of the 27 types). Drugs such as 
dalfampridine, decitabine, defibrotide and figitumumab only were requested from 
this center. In all, the most frequent CU were: bendamustine for lymphoma (12% 
of applications) and 5-aminolevulinic acid for surgery for malignant glioma (12%), 
followed by treprostinil (10%), everolimus (8.2%) and idebenone (8%). The ATC L 
Group (antineoplastic and inmunomodulating) accounted for almost 60% of all CU. 
Stem cell therapy for advanced chronic lower limb ischaemia, diacetylmorphine 
for heroin substitution and norcholesterol (radio drug) were also included as CU. 
After 4 years, 60% of drugs has achieved marketing authorisation. The remaining 
40% have not yet managed license or have been rejected by the EMA (eg 
gentuzumab and idebenone). 
Conclusion: CU showed a variable profile between the different hospitals. Early 
access to certain investigational drugs has been supported by the high percentage 
of marketing authorisations. However, there are uses with some uncertainty. 
